Cited 0 times in Scipus Cited Count

Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.

DC Field Value Language
dc.contributor.authorBae, S-
dc.contributor.authorLee, KJ-
dc.contributor.authorKim, YS-
dc.contributor.authorKim, KN-
dc.date.accessioned2017-01-12T01:42:28Z-
dc.date.available2017-01-12T01:42:28Z-
dc.date.issued2015-
dc.identifier.issn1011-8934-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13401-
dc.description.abstractSmall intestinal bacterial overgrowth (SIBO) can partly explain irritable bowel syndrome (IBS), and rifaximin has been observed to improve abdominal symptoms in nonconstipated IBS patients. However, there are few reports on the association of the rifaximin treatment periods with the results of a lactulose breath test (LBT). Therefore, we performed a retrospective review of patient charts to investigate the relation between the rifaximin treatment periods with LBT results in nonconstipated IBS patients. We also evaluated the time to achieve a symptomatic improvement in the IBS patients as compared to the changes in the LBT. We reviewed the charts for patients who showed IBS symptoms with documented positive results for LBT during their initial visit and who had a follow-up LBT after treatment with rifaximin. The LBT values were compared to the subjects' symptom scores. A total of 102 subjects had a follow-up LBT to assess LBT normalization. The subjects were divided into groups according to treatment periods of 4 weeks (n = 36), 8 weeks (n = 43), and 12 weeks (n = 23). The groups with a longer treatment exhibited an increase in the hydrogen gas value at 90 min and its sum during 90 min at the initial LBT. There were significant differences in hydrogen gas value at 90 min and in its sum during 90 min at the initial LBT between the groups treated for 4 and 12 weeks. The most significant treatment response was observed during the first 4 weeks for all treatment groups. Symptomatic improvement occurred earlier than LBT normalization in the treatment period over 4 weeks. The results indicate that different rifaximin treatment periods are needed in accordance with LBT levels to effectively eradicate SIBO.-
dc.language.isoen-
dc.subject.MESHBiomarkers-
dc.subject.MESHBreath Tests-
dc.subject.MESHConstipation-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHDrug Monitoring-
dc.subject.MESHFemale-
dc.subject.MESHGastrointestinal Agents-
dc.subject.MESHHumans-
dc.subject.MESHIrritable Bowel Syndrome-
dc.subject.MESHLactulose-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHReproducibility of Results-
dc.subject.MESHRifamycins-
dc.subject.MESHSensitivity and Specificity-
dc.subject.MESHTreatment Outcome-
dc.titleDetermination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.-
dc.typeArticle-
dc.identifier.pmid26028929-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444477/-
dc.contributor.affiliatedAuthor이, 광재-
dc.contributor.affiliatedAuthor김, 규남-
dc.type.localJournal Papers-
dc.identifier.doi10.3346/jkms.2015.30.6.757-
dc.citation.titleJournal of Korean medical science-
dc.citation.volume30-
dc.citation.number6-
dc.citation.date2015-
dc.citation.startPage757-
dc.citation.endPage762-
dc.identifier.bibliographicCitationJournal of Korean medical science, 30(6). : 757-762, 2015-
dc.identifier.eissn1598-6357-
dc.relation.journalidJ010118934-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Journal Papers > School of Medicine / Graduate School of Medicine > Family Practice & Community Health
Files in This Item:
26028929.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse